Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2017 17:37 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
June 04, 2017 09:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced that a poster featuring initial clinical data from the ongoing Phase 1/2 clinical...
June 03, 2017 09:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced that a poster featuring updated data from the ongoing Phase 1 trial of FPA144 was...
May 15, 2017 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Welcomes Garry Nicholson to Board of Directors

SOUTH SAN FRANCISCO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
May 04, 2017 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Announces First Quarter 2017 Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
April 20, 2017 16:10 ET | Source: Five Prime Therapeutics, Inc.

Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
April 20, 2017 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4

SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
April 10, 2017 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)

SOUTH SAN FRANCISCO, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that it has completed enrollment in the initially planned 30-patient...
April 03, 2017 13:00 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
April 03, 2017 08:00 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...